BioStem Technologies, Inc. - 10-Q Filing
BioStem Technologies reports Q3 2026 results featuring complex capital structure including Series A and B convertible preferred shares and multiple bridge loan notes.
Tickers: $BSEM
BioStem Technologies reports Q3 2026 results featuring complex capital structure including Series A and B convertible preferred shares and multiple bridge loan notes.
Tickers: $BSEM